EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Geert R. D'Haens  1     Marla C. Dubinsky  2     Peter Irving  3     Xingyuan Li  4     Stefanie Howaldt  5     Juris Pokrotnieks  6     Kathryn Krueger  6     Janelle Laskowski  6     Trevor Lissoos  6     Joe Milata  6    
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
2 Icahn School of Medicine at Mount Sinai, New York City, United States
3 Guy´s and St Thomas´ Hospital, London, United Kingdom
4 Eli Lilly and Company, Indianapolis, United States
5 Research Institute for IBD-HaFCED e.K., Hamburg, Germany
6 Riga Stradins University, Riga, Latvia

Topic
IBD, Nurses, Primary Care

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing